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Abstract
Background: Friedreich ataxia (FRDA) is caused by a homozygous GAA repeat expansion mutation within intron 1
of the FXN gene, which induces epigenetic changes and FXN gene silencing. Bisulfite sequencing studies have
identified 5-methylcytosine (5mC) DNA methylation as one of the epigenetic changes that may be involved in this
process. However, analysis of samples by bisulfite sequencing is a time-consuming procedure. In addition, it has
recently been shown that 5-hydroxymethylcytosine (5hmC) is also present in mammalian DNA, and bisulfite
sequencing cannot distinguish between 5hmC and 5mC.
Methodology/Principal Findings: We have developed specific MethylScreen restriction enzyme digestion and
qPCR-based protocols to more rapidly quantify DNA methylation at four CpG sites in the FXN upstream GAA region.
Increased DNA methylation was confirmed at all four CpG sites in both FRDA cerebellum and heart tissues. We have
also analysed the DNA methylation status in FRDA cerebellum and heart tissues using an approach that enables
distinction between 5hmC and 5mC. Our analysis reveals that the majority of DNA methylation in both FRDA and
unaffected tissues actually comprises 5hmC rather than 5mC. We have also identified decreased occupancy of the
chromatin insulator protein CTCF (CCCTC-binding factor) at the FXN 5’ UTR region in the same FRDA cerebellum
tissues.
Conclusions/Significance: Increased DNA methylation at the FXN upstream GAA region, primarily 5hmC rather
than 5mC, and decreased CTCF occupancy at the FXN 5’ UTR are associated with FRDA disease-relevant human
tissues. The role of such molecular mechanisms in FRDA pathogenesis has now to be determined.
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Introduction
FRDA is an autosomal recessive neurodegenerative
mitochondrial disorder caused primarily by a homozygous GAA
repeat expansion mutation within intron 1 of the FXN gene [1].
Unaffected individuals have up to 43 GAA repeats, while
affected individuals have 44 to 1700 GAA repeats, most
commonly between 600–900 GAA repeats [2,3]. The length of
the smaller GAA repeat correlates with FRDA disease severity
and inversely correlates with the age of onset [4,5]. The effect
of the GAA repeat expansion is to decrease expression of the
essential and ubiquitously expressed mitochondrial frataxin
protein, with levels in FRDA patients ranging from 4% to 29%
that of normal [6]. Reduced levels of frataxin in FRDA patients
are associated with defects of iron–sulphur (Fe–S) cluster
biosynthesis [7], mitochondrial iron accumulation in the heart,
spinal cord and dentate nucleus of the cerebellum [8] and
increased susceptibility to oxidative stress [9].
Two main hypotheses have been proposed to link FXN GAA
repeat expansions with decreased frataxin expression. Firstly,
evidence from in vitro and cell transfection studies suggests
that GAA repeat expansions may adopt abnormal non-B DNA
structures (triplexes or “sticky DNA”) or DNA•RNA hybrid
structures (R-loops), which impede the process of RNA
polymerase II and thus reduce FXN gene transcription [10,11].
Secondly, there is evidence that GAA repeat expansions can
induce heterochromatin-mediated gene silencing effects [12].
Consistent with the latter hypothesis, several FRDA-related
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epigenetic changes have been identified in the immediate
vicinity of the expanded GAA repeats of the FXN gene [13]. An
initial investigation of DNA methylation of the FXN gene by
bisulfite sequencing revealed hypermethylation of the cytosine
residue of specific CpG sites upstream of the GAA repeat
sequence in FRDA patient lymphoblastoid cells compared to
cells derived from unaffected individuals [14]. We have
subsequently used bisulfite sequencing to identify increased
DNA methylation at the upstream GAA repeat region in FRDA
patient cerebellum and heart autopsy tissues, which are
clinically relevant tissues in FRDA [15]. Interestingly, we also
identified reduced levels of DNA methylation in the downstream
GAA repeat region in FRDA patient tissues compared with
controls. These findings have now been confirmed by bisulfite-
based EpiTYPER MassARRAY analysis of blood and buccal
cell samples from a large cohort of FRDA patients, where a
significant inverse correlation was also detected between the
level of DNA methylation in the upstream GAA region and the
level of FXN expression [16]. Yet another study has shown that
the degree of DNA methylation in the upstream GAA repeat
region in FRDA patients correlates with the length of the GAA
repeats and inversely correlates with the age of disease onset
[17]. Therefore, there is good evidence that DNA methylation
may have some role to play in the molecular mechanism of
GAA repeat induced FRDA disease. However, bisulfite
sequencing is a somewhat time-consuming procedure.
Therefore, we now report a more rapid MethylScreen restriction
enzyme digestion and qPCR procedure, which we have
validated by confirming increased DNA methylation at the
upstream GAA repeat region in FRDA patient cerebellum and
heart autopsy tissues.
Methylation of mammalian DNA primarily occurs as 5mC
modification of CpG dinucleotides. However, recent studies
have revealed the existence of an alternative modification,
5hmC, which is formed by oxidation of 5mC by ten-eleven
translocation (TET) enzymes [18,19]. The overall levels of
5hmC in the mammalian genome are approximately 10% of
5mC levels [20], although higher levels have been detected in
tissues of the central nervous system [21]. For example, 5hmC
is approximately 40% as abundant as 5mC in the DNA of
Purkinje cells of the cerebellum [18]. There are two main
theories regarding the function of 5hmC. Firstly, 5hmC may be
an intermediate in the removal of 5mC by an active
demethylation process that involves the base excision repair
pathway [22]. Secondly, 5hmC may be an epigenetic
modification in its own right, regulating chromatin or
transcriptional factors involved in processes such as
neurodevelopment [23]. Therefore, it is possible that 5hmC
may also be involved in epigenetic-based disease
mechanisms, such as those proposed for FRDA. However,
useful information cannot be obtained from previous bisulfite
sequence DNA methylation data, because this method does
not distinguish between 5mC and 5hmC [24]. Therefore, we
have analysed the DNA methylation status of one of the FXN
upstream GAA CpG sites in FRDA cerebellum and heart
tissues using a procedure that does allow distinction between
5hmC and 5mC and we report that the majority of the
methylated DNA at this CpG residue comprises 5hmC rather
than 5mC.
In addition, another factor that has been proposed to be
involved in silencing of the FXN gene in FRDA is the chromatin
insulator protein CTCF, because decreased occupancy of
CTCF has been identified at the FXN 5’ UTR region of FRDA
fibroblast cells [25]. Therefore, we have decided to further
investigate CTCF occupancy in FRDA cerebellum tissue and
we report decreased occupancy of CTCF at the FXN 5’ UTR
region. Overall we show that increased 5hmC at the FXN
upstream GAA region and decreased CTCF occupancy at the
FXN 5’ UTR are both associated with FRDA disease-relevant
human tissues.
Materials and Methods
DNA preparation from human tissues
Human cerebellum and heart tissue samples were obtained
from autopsies of four FRDA patients (aged 17, 24, 36 and 47,
each homozygous for GAA repeat expansions within the range
of approximately 550-750 units) and four unaffected individuals
(aged 69-82, obtained from NDRI). Research ethical approval
was obtained from the SHSSC Research Ethics Committee,
Brunel University, and samples were obtained with written
consent and were stored in accordance with UK Human Tissue
Authority ethical guidelines. For the FRDA patient aged 17,
written informed consent was obtained from the next of kin
under the organisation of the Friedreich’s Ataxia Group tissue
donor scheme. Genomic DNA was isolated from frozen tissues
by standard phenol/chloroform extraction and ethanol
precipitation.
MethylScreen analysis
Four CpG sites in the FXN upstream GAA repeat region,
designated 3, 6, 11 and 13 (numbered according to [14], Figure
1), were investigated using adaptations of the previously
described MethylScreen assay [26]. 1µg of genomic DNA was
digested with: (1) a methylation-sensitive restriction enzyme
(MSRE), (2) a methylation-dependent restriction enzyme
(MDRE), (3) both MSRE and MDRE (double digest, DD), and
(4) neither MSRE or MDRE (mock control). The MSREs used
for CpGs 3, 6, 11 and 13 were AciI (Fermentas), Hpy188III
(New England Biolabs), AjiI (Fermentas) and Eco72I
(Fermentas), respectively. The MDRE used for all four CpGs
was McrBc (Fermentas). A 50ng aliquot of digested DNA was
then amplified by quantitative PCR using SYBR® Green
(Applied Biosystems) and an ABI7900HT Fast Real-Time PCR
System with the following primers: CpG3 F 5’-
GAGACGTGGCTTTGTTTTCTG-3’ and R 5’-
GTTTCCTCCTTTCAAGCCGTG-3’; CpG6 F 5’-
GAAGATGCCAAGGAAGTGGTAG-3’ and R 5’-
GAGCAACACAAATATGGCTTGG-3’; CpG11 and CpG13 F-
met 5’-GAACCGTCTGGGCAAAGGCCAG-3’ and R-met 5’-
ATCCCAAAGTTTCTTCAAACACAATG-3’. PCR quantification
was carried out using the ΔCt method (values were calculated
as 2 ΔCt (mock – digest) with the mock value set at 100%) and RQ
Manager software (Applied Biosystems). Each qPCR reaction
for each sample was performed in triplicate in a 96-well plate.
5hmC and CTCF Changes in FRDA Tissues
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MethylScreen DNA methylation values were then calculated as
follows: Densely methylated (DM) = (MSRE-DD)/(100-DD) x
100; unmethylated (UM) = (MDRE-DD)/(100-DD) x 100;
intermediately methylated (IM) = 100 - (DM+UM).
5hmC analysis
Levels of 5mC and 5hmC were determined at CpG site 12
(numbered according to [14]) of the FXN upstream GAA repeat
region (Figure 1) using the EpiMarkTM Analysis Kit (New
England Biolabs). 1µg genomic DNA was glucosylated with T4
B-glucosyltransferase (T4-BGT), and then both glucosylated
(G) and non-glucosylated (NG) DNA samples were digested
with the methylation sensitive restriction enzyme, HpaII, or the
methylation insensitive restriction enzyme, MspI. Digested
DNA, together with non-digested (mock control) DNA samples
were then amplified by quantitative PCR using SYBR® Green
(Applied Biosystems) on an ABI7900HT Fast Real-Time PCR
System with F-met and R-met PCR primers (the same as used
for MethylScreen analysis). PCR quantification was carried out
using the ΔCt method (values were calculated as 2 ΔCt (mock+G –
digest) with the mock+G value set at 100%) and RQ Manager
software (Applied Biosystems). Each qPCR reaction for each
sample was performed in duplicate in a 96-well plate.
CTCF electrophoretic mobility shift assay (EMSA)
EMSA was performed with recombinant CTCF protein and
three γ-32P end-labelled FXN probes, together with CTCF-
positive (DM1 (1)) and CTCF-negative (DM1 (3)) probes [27].
The probes were prepared by PCR amplification of human
genomic DNA using the following primer pairs: FXN 5’ UTR, F
5’-AAGCAGGCTCTCCATTTTTG-3’, R 5’-
CGAGAGTCCACATGCTGCT-3’; FXN GAA Upstream, F 5’-
GAAACCCAAAGAATGGCTGTG-3’, R 5’-
TTCCCTCCTCGTGAAACACC-3’; FXN GAA Downstream, F
5’-TGGGTTGTCAGCAGAGTTGT-3’, R 5’-
CCGATAATCCCAGCTACTCG-3’; DM1 (1), F 5’-
GCCTGCCAGTTCACAACC-3’, R 5’-
AGCAGCATTCCCGGCTAC-3’; DM1 (3), F 5’-
AGCTTTCTTGTGCATGACG-3’, R 5’-
GGTTGTTGGGGGTCCTGTAG-3’. PCR products were gel
purified using Geneclean III (BIO 101) and end-labelled with
Figure 1.  FXN region of analysis.  Schematic diagram of
2.5kb of the FXN exon 1 and intron 1 region showing the GAA
repeat within an Alu sequence (light grey box), together with
the regions of 5mC/5hmC MethylScreen (dark grey box) and
5hmC EpiMarkTM (black box) analysis. The numbers represent
the CpG sites, which are numbered according to [13]. Asterisks
indicate the positions of the three potential CTCF binding sites
that were analysed by EMSA.
doi: 10.1371/journal.pone.0074956.g001
γ-32P ATP using T4 polynucleotide kinase. Labelled PCR
products were put through a Microspin S-200 HR column (GE
HealthCare) and then incubated with 0.2µg of CTCF full-length
recombinant protein (Abnova) in PBS buffer containing 5mM
MgCl2, 0.1mM ZnSO4, 1mM DTT, 0.1% Nonidet P-40, 10%
glycerol and 1µg of double-strand competitor DNA poly(dI-dC)
(Sigma). After incubation for 30 minutes at room temperature,
samples were run on a 5% nondenaturing polyacrylamide gel
in 0.5X TBE buffer at 100V for 1-2 hours. Gels were then
vacuum dried and exposed to ECL Hyperfilm (GE HealthCare),
followed by film development.
CTCF chromatin immunoprecipitation (ChIP)
Human cerebellum tissue samples (30mg from each of three
FRDA and three unaffected controls, the same as used for
DNA preparation) were homogenised, followed by cross-linking
of DNA and protein by formaldehyde treatment. Cell nuclei
were isolated by centrifugation and then lysed in the presence
of protease inhibitors [15]. DNA was sheared by sonication,
followed by immunoprecipitation with anti-CTCF antibody
(Upstate 07-729). After reversal of cross-linking, qPCR
amplification of the resultant co-immunoprecipitated DNA was
carried out with SYBR® Green in an ABI7400 sequencer
(Applied Biosystems) using FXN 5’ UTR primers and GAPDH
(negative for CTCF) control primers as previously described
[25]. PCR quantification was carried out using the ΔΔCt
method and RQ Manager software (Applied Biosystems). Each
value of immunoprecipitated DNA was normalised to both input
and GAPDH values. Each tissue sample was subjected to four
independent ChIP procedures, followed by triplicate qPCR
analysis.
Statistical analysis
Comparison of data from FRDA patients and unaffected
control samples was carried out using the student’s t test with a
significance value set at P<0.05.
Results
MethylScreen analysis is a rapid method to quantify
DNA methylation in the FXN upstream GAA repeat
region
We, and others, have previously used bisulfite sequencing to
quantify DNA methylation changes at the FXN upstream GAA
repeat region in FRDA cells and tissues [14–17]. However,
bisulfite sequencing is a somewhat time-consuming procedure,
which can be subject to errors due to incomplete bisulfite
treatment. Therefore, we have now adapted the previously
described MethylScreen assay [26] to rapidly quantify the DNA
methylation status at four CpG sites at the FXN upstream GAA
repeat region, designated 3, 6, 11 and 13 according to [14]
(Figure 1). The MethylScreen method does not require bisulfite
treatment of DNA, but involves digestion of genomic DNA with
a MSRE, a MDRE, and both a MSRE and a MDRE, followed by
qPCR amplification of the residual non-digested DNA using an
amplicon that spans the CpG site of interrogation. The output
data is expressed as three levels of DNA methylation status:
5hmC and CTCF Changes in FRDA Tissues
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unmethylated (UM), intermediately methylated (IM) and
densely methylated (DM). We validated the MethylScreen
assay by investigating the levels of DNA methylation at CpG11
and CpG 13 in cerebellum and heart tissue from FRDA patients
and unaffected controls, which allowed a direct comparison
with our previously reported bisulfite sequence analysis [15]. In
addition, we investigated CpG3 and CpG6 in cerebellum and
heart tissue, since these sites together with CpG13 have
previously been identified as the three sites of most significant
DNA methylation increase in FRDA versus control
lymphoblastoid cells [14]. Our results for cerebellum tissue
reveal an increase in DNA methylation at all four CpG sites in
FRDA tissue compared with unaffected control tissue, in
agreement with all previous bisulfite sequencing data (Figure
2). However, the magnitude of this DNA methylation increase
was found to vary from a non-statistically significant small
increase in DM of 6% to 20% at CpG3, through an intermediate
level of increase in DM of 4% to 68% at CpG6 (P<0.001), to
high levels of increase in DM of 14% to 96% at both CpG11
and CpG13 (both P<0.001). The results for heart tissue also
reveal significant increases in DNA methylation at all four CpG
sites in FRDA tissue compared with unaffected control tissue,
with DM values increasing from 0% to 93% at CpG3 (P<0.001),
15% to 92% at CpG6 (P<0.001), 32% to 83% at CpG11
(P<0.01) and 21% to 97% at CpG13 (P<0.001), again in
agreement with all previous bisulfite sequencing data (Figure
3). Therefore, the specific MethylScreen protocols that we have
developed can be considered as both rapid and robust
procedures to investigate DNA methylation status at the FXN
locus.
Figure 2.  DNA methylation levels in
cerebellum.  MethylScreen analysis of four CpG sites in the
FXN upstream GAA repeat region of DNA from FRDA and
control cerebellum tissues. UM = unmethylated, IM =
intermediately methylated, DM = densely methylated. Error
bars = s.e.m. n=4.
doi: 10.1371/journal.pone.0074956.g002
5hmC is the predominant constituent of DNA
methylation in the FXN upstream GAA repeat region
and is increased in FRDA cerebellum and heart tissues
Levels of 5mC and 5hmC were determined at CpG site 12 of
the FXN upstream GAA repeat region (Figure 1) using the
EpiMarkTM Analysis Kit (New England Biolabs). This CpG site
was chosen because it resides within a CCGG motif, which is
required by the EpiMarkTM procedure for differential restriction
enzyme digestion by HpaII and MspI. The principle of this
technique depends on the addition of glucose to the hydroxyl
group of 5hmC via an enzymatic reaction utilising T4-BGT.
Genomic DNA is glucosylated, then digested with a methylation
sensitive restriction enzyme, HpaII, and a methylation
insensitive restriction enzyme, MspI. If 5hmC is present in the
context of CCGG, this modification converts a normally
cleavable MspI site to a non-cleavable one.
Initial determination of DNA methylation levels (combined
5mC and 5hmC) by observing HpaII + G and HpaII qPCR
values at CpG12 in cerebellum tissue reveals a significant
increase in DNA methylation in FRDA tissue compared with
unaffected control tissue (Figure 4A), at levels similar to those
previously identified by bisulfite sequencing. Thus, DNA
methylation levels increase from either 36% to 77% (HpaII + G,
P<0.01) or 30% to 87% (HpaII, P<0.05) compared with
previously reported bisulfite sequence values of 40% to 95%
[15]. However, more detailed analysis reveals that there is no
difference in the MspI + G and HpaII + G qPCR results from
unaffected cerebellum tissues, and similarly there is no
difference in the MspI + G and HpaII + G qPCR results from
FRDA cerebellum tissues (Figure 4A). This indicates that all
methylated DNA in both the unaffected and the FRDA
cerebellum tissue comprises 5hmC rather than 5mC.
Therefore, we can now conclude that a characteristic feature of
FRDA cerebellum tissue is an increase in 5hmC-modified DNA
Figure 3.  DNA methylation levels in heart.  MethylScreen
analysis of four CpG sites in the FXN upstream GAA repeat
region of DNA from FRDA and control heart tissues. UM =
unmethylated, IM = intermediately methylated, DM = densely
methylated. Error bars = s.e.m. n=4.
doi: 10.1371/journal.pone.0074956.g003
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in the FXN upstream GAA repeat region, at least at CpG site
12. Determination of DNA methylation levels (combined 5mC
and 5hmC) in heart tissue also reveals a significant increase in
DNA methylation in FRDA tissue compared with unaffected
control tissue (Figure 4B), at levels similar to those previously
identified by bisulfite sequencing. Thus, DNA methylation levels
increase from either 44% to 100% (HpaII + G, P<0.01) or 37%
to 89% (HpaII, P<0.001) compared with previously reported
bisulfite sequence values of 65% to 95% [15]. However, more
detailed analysis of the MspI + G compared with HpaII + G
qPCR results indicates that the methylated DNA comprises
approximately 64% 5hmC in the unaffected heart tissues and
only 37% 5hmC in the FRDA heart tissues, although there is
still an overall increase in 5hmC levels (MspI + G values) in
FRDA compared with controls (Figure 4B). This suggests that,
while there is increased DNA methylation in both cerebellum
and heart tissues, there are also tissue specific differences:
DNA methylation is entirely due to 5hmC in the cerebellum, but
only partially due to 5hmC in the heart.
CTCF occupancy at the FXN 5’ UTR region is decreased
in FRDA cerebellum tissue
We firstly performed in silico screening of a 40kb region
spanning the FXN gene for potential CTCF binding sites using
the bioinformatics web tool designed by Klenova and
colleagues (http://www.essex.ac.uk/bs/molonc/spa.htm) and
we identified three regions of interest at the start of the FXN
gene. We then investigated the three potential CTCF binding
regions, which were located within the 5’ UTR, GAA upstream
and GAA downstream regions of the FXN locus (Fig 1), by
EMSA using recombinant full length CTCF protein. Only the 5’
UTR probe proved capable of binding CTCF protein to cause a
gel shift (Figure 5A). This result is in agreement with a previous
report that identified CTCF binding in the FXN 5’ UTR region
using fibroblast cell lysates [25]. We then performed ChIP
analysis to assess the level of CTCF binding at the 5’ UTR site
in three FRDA cerebellum tissue lysates compared with three
unaffected controls, using the same qPCR amplicons as
previously described [25]. A statistically significant decrease
(P<0.05) in CTCF binding was detected in FRDA cerebellum,
with levels falling to only 20% of the levels detected in
unaffected cerebellum controls (Figure 5B).
Discussion
We have investigated two molecular mechanisms that may
be involved in the disease process in FRDA patient cerebellum
and heart tissues. Firstly, we have developed a rapid and
robust MethylScreen method to determine the general DNA
methylation status (5mC and 5hmC) at the FXN upstream GAA
repeat region. The level of DNA methylation in FRDA
cerebellum tissue showed a gradation across the four CpG
sites investigated, progressively increasing as you move closer
to the GAA repeat locus. This suggests that the GAA repeat
expansion mutation may act as focal point to induce only a
localised effect of DNA methylation, spreading upstream from
this point. However, this gradation effect was not seen in FRDA
heart tissue, which demonstrated high levels of DNA
methylation at all 4 CpG sites, indicating a degree of variability
in the DNA methylation process in different FRDA tissues.
Such variability may have some bearing on the previously
identified differences in GAA repeat somatic instability, with
cerebellum showing high levels of instability, while heart is
comparatively stable [28].
Subsequently, we have shown that the methylated DNA at
one CpG site in the FXN upstream GAA region comprises
entirely 5hmC in FRDA cerebellum, but only partially 5hmC in
FRDA heart. Our results are in agreement with the recent
report that 5hmC is particularly associated with human
cerebellum throughout development [29]. However, we can
discount the possibility that the increased 5hmC that we have
observed in FRDA tissues is a non-specific age-related effect
in neuronal tissues, as previously reported for mouse
hippocampus and cerebellum [23,30], because our FRDA
patients are actually younger than the unaffected controls.
Figure 4.  5hmC levels in cerebellum and heart.  EpiMarkTM
5hmC and 5mC analysis of CpG site 12 in the FXN upstream
GAA repeat region of DNA from FRDA and control cerebellum
(A) and heart (B) tissues. G = glucosylated DNA. MspI values
represent complete digestion control levels of DNA; MspI + G
represents 5hmC levels, HpaII and HpaII + G represent
combined 5mC and 5hmC levels; Mock and Mock +G
represent undigested control levels of DNA. Error bars = s.e.m.
n=4.
doi: 10.1371/journal.pone.0074956.g004
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Further studies will be required to determine if our finding is a
general increased 5hmC effect for CpG sites within the FXN
upstream GAA region, or indeed within other regions of the
genome. The high levels of 5hmC that we have detected at the
FXN upstream GAA region could be explained by either a
passive or an active process. Thus, 5hmC could merely be a
non-functioning intermediate in a demethylation process that is
attempting to reverse the GAA repeat expansion-induced 5mC
DNA methylation that is associated with FXN gene silencing
[17]. In this case, the differences that we have detected
between 5hmC levels in cerebellum and heart tissues could
perhaps be due to tissue-selective differences in the efficiency
Figure 5.  CTCF analysis.  (A) EMSA showing a mobility shift
for the FXN 5’ UTR probe and CTCF-positive DM1 (1) probe
[35], while there is no such shift detected for the FXN upstream
GAA (Up) probe, FXN downstream GAA (Down) probe or
CTCF-negative DM1 (3) probe [35]. (B) ChIP analysis showing
the relative CTCF occupancy in the FXN 5’ UTR of DNA from
FRDA and control cerebellum tissues. Error bars = s.e.m. n=3.
* = P<0.05.
doi: 10.1371/journal.pone.0074956.g005
of the TET enzymes that convert 5mC to 5hmC [18,19] or the
DNA repair systems (e.g. base excision repair) that are
required to convert 5hmC to cytosine [22]. Alternatively, 5hmC
may have an as yet unidentified role in regulation of gene
expression. For example, it has shown in vitro that 5hmC at the
promoter but not in the gene body negatively regulates gene
expression [31]. Furthermore, it has been proposed that 5hmC
may be involved in the regulation of genes that are silent but
transcriptionally poised for activation, where there is loss of
5mC, recruitment of Polycomb repressive complex 2 (PRC2)
and, therefore, methylation of histone 3 at lysine 27
(H3K27me3) [20]. Indeed, 5hmC and H3K27me3 have been
shown to have high correlation across a variety of somatic
tissues [32]. Therefore, it is interesting to note that the FXN
gene demonstrates RNA polymerase II pausing and FRDA
lymphoblastoid cells have shown increased levels of
H3K27me3 in the FXN upstream GAA repeat region [33,34]. In
addition, it has been proposed that 5hmC may inhibit DNMT1
binding and may therefore function as a negative regulator of
5mC levels at protein-DNA interaction sites, allowing the
binding of enhancer proteins or transcription factors [35].
Furthermore, 5hmC has been reported to bind MECP2,
particularly in the CNS, although the functional consequences
of such an interaction are not yet known [36]. Although the
close positioning of the GAA repeat expansion mutation and
the increased 5hmC modification of DNA in the FXN upstream
GAA repeat region in FRDA would suggest a likely causal
relationship, there may also be other more general factors
involved in the formation of 5hmC. For example, the TET
enzymes that produce 5hmC are known to be dependent on
Fe(II) and α-ketoglutarate. Therefore, disruptions of iron
metabolism, oxidative stress and the TCA cycle, processes
which are highly relevant to FRDA, may all potentially affect
5hmC levels [37].
The second molecular change that we have identified in
FRDA cerebellum is reduced CTCF occupancy at the FXN 5’
UTR region, confirming previous findings in FRDA fibroblast
cells [25]. It has been hypothesized that decreased binding of
CTCF in FRDA cells may be an epigenetic switch that allows
increased frataxin antisense (FAST-1) transcription, spread of
heterochromatin and resultant FXN gene silencing. DNA
methylation has not been thought to play an active role in this
process, because increased DNA methylation has not been
detected at the CTCF binding site in the FXN 5’ UTR region of
FRDA cells or tissues [15,16,25], and the increased DNA
methylation at the FXN upstream GAA repeat region has been
considered to be an unconnected marker of the
heterochromatin state. However, if there is a demethylation
process occurring at the FXN upstream GAA repeat region, as
indicated by the high levels of 5hmC that we have now
identified, then this may indeed be involved in increasing
FAST-1 expression, CTCF depletion and hence FXN gene
silencing. In conclusion, we can propose a model for FRDA
that combines both the increased 5hmC modification of DNA
and decreased CTCF binding at the FXN locus. Further studies
will now be required to determine the exact relationship
between these molecular mechanisms and FRDA
pathogenesis.
5hmC and CTCF Changes in FRDA Tissues
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